Literature DB >> 12359692

Elevated homocysteine levels in young male patients with schizophrenia.

Joseph Levine1, Ziva Stahl, Ben Ami Sela, Slava Gavendo, Vladimir Ruderman, Robert H Belmaker.   

Abstract

OBJECTIVE: Elevated plasma homocysteine has been found to be a risk factor for Alzheimer's disease as well as cerebral vascular disease, suggesting that some risk factors can accelerate or increase the severity of several CNS disease processes. The authors measured plasma homocysteine levels in patients with chronic schizophrenia in their catchment area.
METHOD: A one-way analysis of covariance with age and sex as covariates was performed on the total plasma homocysteine levels of 193 patients with schizophrenia compared with 762 subjects without the diagnosis of schizophrenia who were evaluated in a screening program for employee health.
RESULTS: The effect of schizophrenia was marked: the mean homocysteine level was 16.3 micro M (SD=11.8) in patients with schizophrenia compared with 10.6 micro M (SD=3.6) in healthy comparison subjects. The difference between groups was almost entirely attributable to the homocysteine levels of young male patients with schizophrenia.
CONCLUSIONS: Elevated levels of homocysteine in young male patients with schizophrenia could be related to the pathophysiology of aspects of this illness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359692     DOI: 10.1176/appi.ajp.159.10.1790

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  25 in total

1.  Glycine N-methyltransferase expression in the hippocampus and its role in neurogenesis and cognitive performance.

Authors:  Manuel Carrasco; Luis G Rabaneda; Maribel Murillo-Carretero; Sylvia Ortega-Martínez; María L Martínez-Chantar; Ashwin Woodhoo; Zigmund Luka; Conrad Wagner; Shelly C Lu; José M Mato; Juan A Micó; Carmen Castro
Journal:  Hippocampus       Date:  2014-04-08       Impact factor: 3.899

2.  Chromatin from peripheral blood mononuclear cells as biomarkers for epigenetic abnormalities in schizophrenia.

Authors:  David P Gavin; Rajiv P Sharma
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-07-22

3.  Epigenetic mechanisms in the pathophysiology of psychotic disorders.

Authors:  W Brad Ruzicka
Journal:  Harv Rev Psychiatry       Date:  2015 May-Jun       Impact factor: 3.732

4.  Homocysteine and cognition in first-episode psychosis patients.

Authors:  Rosa Ayesa-Arriola; Rocío Pérez-Iglesias; José Manuel Rodríguez-Sánchez; Ignacio Mata; Elsa Gómez-Ruiz; Maite García-Unzueta; Obdulia Martínez-García; Rafael Tabares-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-02       Impact factor: 5.270

5.  The glutamate agonist homocysteine sulfinic acid stimulates glucose uptake through the calcium-dependent AMPK-p38 MAPK-protein kinase C zeta pathway in skeletal muscle cells.

Authors:  Ji Hae Kim; Jung Ok Lee; Soo Kyung Lee; Ji Wook Moon; Ga Young You; Su Jin Kim; Sun-Hwa Park; Ji Man Park; Se Young Lim; Pann-Ghill Suh; Kyung-Ok Uhm; Min Seok Song; Hyeon Soo Kim
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

6.  Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures.

Authors:  David P Gavin; Cherise Rosen; Kayla Chase; Dennis R Grayson; Nguwah Tun; Rajiv P Sharma
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

Review 7.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

8.  Homocysteine reduces NMDAR desensitization and differentially modulates peak amplitude of NMDAR currents, depending on GluN2 subunit composition.

Authors:  Andrew D Bolton; Marnie A Phillips; Martha Constantine-Paton
Journal:  J Neurophysiol       Date:  2013-07-17       Impact factor: 2.714

9.  Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

Authors:  Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr
Journal:  Schizophr Res       Date:  2007-10-31       Impact factor: 4.939

10.  Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Authors:  Donald C Goff
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.